Research and Developments

Page 5 of 19« First...34567...10...Last »

November 16, 2015

Iluvien Similar to Anti-VEGF Drugs as Treatment for Diabetic Retinopathy

Posted in: Latest News, Research and Developments, Therapies, Treatments, and Procedures

On February 16, Charles C. Wykoff, MD, PhD, announced to the American Academy of Ophthalmology annual meeting that Iluviuan (fluocinolone acetonide) treatment, after 1.3 injections over 3 years in the FAME trials, “significantly reduced progression to prolific diabetic retinopathy from 31% to 17%, a similar reduction as observed with monthly anti-VEGF treatments.” Iluvian (Alimera Sciences)
read more »

October 27, 2015

RXI-109 May Reduce Retinal Scarring

Posted in: Latest News, Research and Developments

New drug silences connective tissue growth factor (CTGF), which plays a key role in tissue regeneration and repair. by Dan Roberts One of the most serious causes of vision loss is development of scar tissue on, in, or under the retina. People can develop retinal scarring from severe myopia, ocular histoplasmosis syndrome, and wet age-related
read more »

September 16, 2015

Diet, exercise, smoking habits, and genes interact to affect AMD risk

Posted in: Latest News, Research and Developments

NIH-funded study points to converging factors that drive disease-related inflammation People with a genetic predisposition for age-related macular degeneration (AMD) significantly increased their odds of developing the blinding eye disorder if they had a history of heavy smoking and consistently did not exercise or eat enough fruits and vegetables, according to an observational study of
read more »

September 8, 2015

Ocata’s Stem Cell Trials Entering Phase 2

Posted in: Latest News, Research and Developments

Results from First Cohort Expected in the Second Quarter of 2016 Acucela (formerly Ocata) has announced that the first patient has been enrolled in the company’s Phase 2 clinical trial using Ocata’s proprietary RPE cells in patients with atrophic (dry) age-related macular degeneration (AMD). The purpose of the trial is to evaluate safety and explore efficacy as compared
read more »

September 4, 2015

Long-term Treatment for Wet AMD Enters Phase 2 Trials

Posted in: Latest News, Research and Developments

Neurotech Pharmaceuticals, Inc. has announced that they have enrolled the first patient in their multicenter Phase 2 clinical trial of NT-503 Encapsulated Cell Therapy (ECT) for the long-term treatment of wet macular degeneration (AMD). NT-503 is a unique vascular endothelial growth factor (VEGF) receptor protein continuously produced by Neurotech’s versatile ECT implant. “This landmark proof-of-concept
read more »

July 19, 2015

Trash-Collecting Cells May Accelerate Retinitis Pigmentosa

Posted in: Latest News, Research and Developments

NIH research points to microglia as potential therapeutic target in retinitis pigmentosa Spider-like cells inside the brain, spinal cord and eye hunt for invaders, capturing and then devouring them. These cells, called microglia, often play a beneficial role by helping to clear trash and protect the central nervous system against infection. But a new study
read more »

June 24, 2015

Orcam Now Available in the U.S.

Posted in: Latest News, Research and Developments

In November 2013, an article appeared here about OrCam, a camera-based system which allows the visually impaired to both read and identify objects with a point of a finger. The device is a small camera connected by a thin cable to a portable computer in the wearer’s pocket. The system clips on to the wearer’s
read more »

June 19, 2015

Cheaper Substitute for Lucentis Developed in India

Posted in: Latest News, Research and Developments

Intas Pharmaceuticals, a company based in India, has launched RAZUMAB™, an anti-VEGF drug that is “biosimilar” to Lucentis. This means that RAZUMAB has a synthesized chemical structure that can substitute for, but not duplicate, Lucentis. To make biosimilarity possible, scientists must show that the new product is highly similar and have no significant differences from
read more »

May 20, 2015

Summary of Research and Development – 2015

Posted in: Latest News, Research and Developments

by Dan Roberts (Also available in audiovisual format) INTRODUCTION This is my 10th annual summary of leading research and developments that have occurred during the past 12 months in the field of blindness and low vision. For more details about any of the reports, sources are provided. Many studies and clinical trials are moving ever
read more »

May 14, 2015

MD Support’s LowViz Guide Offers Gift of Sight

Posted in: Latest News, Research and Developments

For four days, Bill DeMaio could see through walls. And that’s really saying something, considering that he has no eyesight. Until May 10, 2015, Bill could find his way around an unfamiliar building only by either asking people for directions or hoping to find Braille signs. But then, on the first day of the 2015
read more »

Page 5 of 19« First...34567...10...Last »

Custom Wordpress design and web development by Jeff Roberts Web Design

WP-Backgrounds by InoPlugs Web Design and Juwelier Schönmann